Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Stienen, S (Author) Other; Bhatt, A (Author) Other; Ferreira, JP (Author) FMUP; Vaduganathan, M (Author) Other; Januzzi, J (Author) Other; Adams, K (Author) Other; Tardif, JC (Author) Other; Rossignol, P (Author) Other; Zannad, F (Author) Other

Journal

Title: Heart Failure Reviews

Vol. 26

Pages: 11-21

ISSN: 1382-4147

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 1 Citation

Other information

Authenticus ID: P-00S-KCF

DOI: 10.1007/s10741-020-10004-6

Abstract (EN): Treatment of patients with heart failure with reduced ejection fraction (HFrEF) with currently available therapies reduces morbidity and mortality. However, implementation of these therapies is a problem with only few patients achieving guideline-recommended maximal doses of therapy. In an effort to improve guideline adherence and uptitration, several trials have investigated a biomarker-guided strategy (using natriuretic peptide targets in specific), but although conceptually promising, these trials failed to show a consistent beneficial effect on outcomes. In this review, we discuss different methodological issues that may explain the failure of these trials and offer potential solutions. Moreover, alternative approaches to increase heart failure guideline adherence are evaluated.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 11